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Abdominal aortic aneurysm
and autosomal-dominant
polycystic kidney disease
To the Editor: In a recent issue of Kidney International,
Gibbs et al [1] ascertained the risk of growth and rup-
ture of intracranial aneurysms in autosomal-dominant
polycystic kidney disease (ADPKD) patients discov-
ered by presymptomatic screening. It is well known that
ADPKD is associated with a variety of life-threatening
cardiovascular diseases, such as intracranial and coronary
aneurysms [2]. On the other hand, the coexistence of ab-
dominal aortic aneurysm (AAA) has been also reported
in some ADPKD patients [2–5]. Chapman and Hilson
[3] have described three patients (9.7%) with AAA and
polycystic renal failure out of a total 31 patients with
adult polycystic disease who had been on their dialysis
and transplantation program for some time. Roodvoets
[4] has reported an AAA in 1 (5.0%) of 20 patients with
polycystic kidney disease. Kato et al [2] have reported
that the frequency of AAA was 7.1% in ADPKD pa-
tients. Ruptured AAA has been also described [3, 4], and
the technical difficulty of the exposure of the aorta is in-
creased by the presence of voluminous kidneys, causing
delay in cross-clamping during emergency laparotomy for
rupture [5]. A significant increase in the aortic diame-
ters (2.7 ± 0.14 cm) was found in the ADPKD patients
compared with those in the chronic glomerulonephritis
(2.3 ± 0.03 cm) and diabetes mellitus (2.3 ± 0.05 cm)
groups (P < 0.02), and a routine screening of the aortic
size, using computed tomography or echography, is rec-
ommended to detect the presence of AAA in ADPKD
patients [2]. Further studies of screening and follow-up
of AAA in ADPKD patients are needed.
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Fig. 1. Weekly doses of vitamin C derived from recommended daily
allowance for the general population, compared with dosages suggested
for patients on chronic dialysis. From references [1–4].
Protective effect of vitamin C
supplementation in dialysis
patients: Not all that glitters. . .
To the Editor: An elegant study by Tarng et al [1] has
demonstrated that intravenous vitamin C supplementa-
tion as 300 mg postdialysis three times a week reduces
DNA-8-hydroxy-2′deoxyguanosine and reactive oxygen
species in peripheral lymphocytes of dialysis patients.
Its efficacy with serum ferritin < and >500 lg/L speaks
against the worried pro-oxidant effect of vitamin C on
lymphocyte DNA oxidation in case of increased iron
stores.
What would be the actual consequences of introducing
this knowledge in the clinical practice? As in previous
works on erythropoietin therapy, vitamin C as “adjuvant
therapy” at dosages many times higher than that sug-
gested for the general population became recommended
in dialysis patients (Fig. 1), without putting evidence
forward to demonstrate the safety in terms of oxalate
metabolism [2–4].
Major concern for safety of vitamin C supplementation
arises from its metabolism to oxalate, which, in uremic pa-
tients, may exceed the threshold of solubility of calcium
oxalate, and result in tissue deposition of calcium oxalate
crystals, eventually increasing cardiovascular risks and
worsening renal function in predialysis patients.
The gap between theoretical knowledge and actual
demonstration of benefits in major outcomes such as sur-
vival often being large, the ratio “known side effects/
unknown clinical benefits” should be carefully evaluated
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to maintain the imperative of “primum, non nocere.” To
obtain evidence for future guidelines, plasma oxalate con-
centrations should be monitored in this kind of study to
see what happens when plasma ascorbate concentrations
double, or more, as they did in the above-mentioned study
after only eight weeks of supplementation.
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Reply from the Authors
I appreciate the comments by Dr. Canavese et al on
the optimal dose of vitamin C supplementation, and sub-
sequent risk of oxalosis in patients on chronic dialysis.
Plasma oxalate concentrations were examined in our pre-
vious study [1] for hemodialysis patients receiving vi-
tamin C supplementation of 300 mg postdialysis thrice
weekly for eight weeks. The vitamin C level significantly
increased after the first four weeks, and decreased slightly
during the second four-week period (Fig. 1A). In contrast,
plasma oxalate levels did not significantly increase after
eight weeks of intravenous vitamin C; although there was
a modest increase in oxalate level, it was marked only
for the first four weeks, and remained at a similar level
during the second four-week period (Fig. 1B). Thus, it is
speculated that there was no steady increase with time in
plasma oxalate levels in the present study using the same
dose frequency [2].
Hemodialysis patients are at risk for ascorbate defi-
ciency due to its dialytic loss, increased consumption, or
inadequate intake. Most studies documented lower than
normal plasma ascorbate concentrations in nonsupple-
mented hemodialysis patients [3, 4]. Therefore, a supple-
mentation of vitamin C is essential. Excessive vitamin
C treatment may worsen uremic-related oxalosis; how-
ever, supplementation not exceeding 150 mg daily is still
considered a safe dose [5]. Currently, in the case of sus-
pected subclinical ascorbate deficiency, 1 to 1.5 g of oral
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Fig. 1A. Changes of plasma ascorbate and oxalate concentrations in
hemodialysis patients not receiving (white bars, N = 15) and receiv-
ing intravenous vitamin C supplementation with response (black bars,
N = 18) or without (hatched bars, N = 19) during eight weeks of study.
(A) P < 0.05 versus patients not receiving vitamin C supplementation
at four weeks and eight weeks, respectively, and (B) P < 0.05 versus
baselines at week 0 in responders and nonresponders, respectively.
ascorbate weekly for hemodialysis patients, or 300 mg
of parenteral ascorbate three times weekly at the end
of dialysis, is recommended [6, 7]. Although there is no
long-term controlled study showing increasing oxalosis
risk in hemodialysis patients taking 1000 to 1500 mg/wk
of vitamin C, these doses can normalize plasma ascorbate
levels, and are considered safe for up to eight weeks with
respect to the danger of secondary oxalosis. I agree with
Dr. Canavese et al that long-term vitamin C replacement
studies are needed to monitor the oxalate levels, and to
determine the safety and efficacy in chronic kidney dis-
ease patients and those on maintenance dialysis therapy.
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